A detailed history of Barclays PLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Barclays PLC holds 127,060 shares of DNLI stock, worth $3.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
127,060
Previous 151,560 16.17%
Holding current value
$3.41 Million
Previous $3.11 Million 5.08%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$14.96 - $23.22 $366,520 - $568,890
-24,500 Reduced 16.17%
127,060 $2.95 Million
Q1 2024

May 15, 2024

SELL
$15.83 - $23.35 $2.73 Million - $4.03 Million
-172,459 Reduced 53.22%
151,560 $3.11 Million
Q4 2023

Feb 15, 2024

BUY
$16.2 - $23.18 $2.55 Million - $3.65 Million
157,512 Added 94.6%
324,019 $6.95 Million
Q3 2023

Nov 07, 2023

BUY
$20.63 - $30.17 $165,968 - $242,717
8,045 Added 5.08%
166,507 $3.44 Million
Q2 2023

Aug 03, 2023

SELL
$23.37 - $32.96 $11.6 Million - $16.4 Million
-497,965 Reduced 75.86%
158,462 $4.68 Million
Q1 2023

May 04, 2023

BUY
$21.91 - $32.67 $1.54 Million - $2.3 Million
70,462 Added 12.02%
656,427 $15.1 Million
Q4 2022

Feb 13, 2023

BUY
$26.28 - $33.92 $6.85 Million - $8.84 Million
260,498 Added 80.04%
585,965 $16.3 Million
Q3 2022

Nov 03, 2022

SELL
$25.97 - $38.53 $1.12 Million - $1.67 Million
-43,304 Reduced 11.74%
325,467 $9.99 Million
Q2 2022

Aug 12, 2022

BUY
$20.88 - $35.19 $6.49 Million - $10.9 Million
310,639 Added 534.37%
368,771 $10.9 Million
Q1 2022

May 16, 2022

SELL
$29.0 - $47.27 $1.82 Million - $2.96 Million
-62,689 Reduced 51.89%
58,132 $1.87 Million
Q4 2021

Feb 14, 2022

BUY
$42.59 - $55.02 $2.12 Million - $2.74 Million
49,856 Added 70.25%
120,821 $5.39 Million
Q3 2021

Nov 09, 2021

BUY
$48.48 - $78.23 $2.29 Million - $3.69 Million
47,204 Added 198.66%
70,965 $3.58 Million
Q2 2021

Aug 13, 2021

SELL
$50.3 - $78.44 $3.32 Million - $5.18 Million
-66,012 Reduced 73.53%
23,761 $1.87 Million
Q1 2021

May 13, 2021

BUY
$53.8 - $81.53 $3.62 Million - $5.49 Million
67,315 Added 299.74%
89,773 $5.13 Million
Q4 2020

Feb 11, 2021

SELL
$36.89 - $93.56 $234,472 - $594,667
-6,356 Reduced 22.06%
22,458 $1.88 Million
Q3 2020

Nov 12, 2020

SELL
$23.13 - $38.84 $156,705 - $263,141
-6,775 Reduced 19.04%
28,814 $1.03 Million
Q2 2020

Aug 12, 2020

BUY
$16.01 - $28.82 $282,080 - $507,779
17,619 Added 98.05%
35,589 $860,000
Q1 2020

May 13, 2020

SELL
$14.2 - $27.98 $435,911 - $858,930
-30,698 Reduced 63.08%
17,970 $314,000
Q4 2019

Feb 10, 2020

BUY
$14.4 - $19.99 $60,739 - $84,317
4,218 Added 9.49%
48,668 $848,000
Q3 2019

Nov 14, 2019

BUY
$15.32 - $21.92 $207,402 - $296,752
13,538 Added 43.8%
44,450 $681,000
Q2 2019

Aug 14, 2019

BUY
$18.5 - $28.14 $317,904 - $483,557
17,184 Added 125.17%
30,912 $642,000
Q1 2019

May 15, 2019

BUY
$17.99 - $24.65 $246,966 - $338,395
13,728 New
13,728 $319,000
Q4 2018

Feb 14, 2019

SELL
$13.88 - $21.75 $236,945 - $371,294
-17,071 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$12.46 - $21.74 $197,279 - $344,209
15,833 Added 1278.92%
17,071 $371,000
Q2 2018

Aug 14, 2018

SELL
$15.25 - $21.02 $32,009 - $44,120
-2,099 Reduced 62.9%
1,238 $19,000
Q1 2018

May 15, 2018

BUY
$15.36 - $24.8 $51,256 - $82,757
3,337 New
3,337 $65,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.6B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.